As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

The Trump administration has intervened in a long-running lawsuit over the abortion pill mifepristone, asking a federal court judge to dismiss a lawsuit that could have restricted access to the drug.

In the realm of medical research, liver disease remains a complex and often overlooked field. Despite the growing global burden of liver-related diseases, hepatology is still a relatively young ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, Massachusetts ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

The most successful pharma sales teams will be those that define and service customers in new ways. Those who are the most responsive and relevant to today's customers and influencers will reap ...

The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity in some patients, citing a recent study and new data.

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.